Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism; D018849:Controlled Clinical Trials as Topic / Q000379:methods; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects / Q000502:physiology
D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; C522667:asenapine